The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Aurobindo Pharma gets U.S. FTC go-ahead to acquire Lannett Company | 0 | 0 | 22-06-2026 |
| 2 | FTC Tells 4th Circ. Court Got It Wrong In J&J Stelara Case | 0 | 5 | 23-06-2026 |
| 3 | IT Distributor Accused Of Withholding $27M In Tax Benefits | 0 | 0 | 17-06-2026 |
| 4 | Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans | 0 | 5 | 23-06-2026 |
| 5 | Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win | 0 | 0 | 17-06-2026 |
| 6 | Robodebt class action settlement approved | 0 | 0 | 23-06-2026 |
| 7 | SEC Settles Insider Trading Suit Against Biotech Investor | 0 | 0 | 16-06-2026 |
| 8 | European Union Lawmakers Approve Much-Delayed Trade Deal With U.S. | 0 | 0 | 16-06-2026 |
| 9 | Calif., Carbon Health $4.5M Deal Over Clinic Biz Nears Review | 0 | 0 | 18-06-2026 |
